Literature DB >> 8239229

Primary central nervous system lymphoma.

H A Fine1, R J Mayer.   

Abstract

OBJECTIVE: To compare the pathogenesis, clinical presentation, therapy, and prognosis of primary central nervous system lymphoma in immunocompetent persons with these characteristics of the disease in patients with AIDS. DATA SOURCES AND EXTRACTION: All English-language papers published between 1980 and 1992 dealing with either lymphoma and the central nervous system or AIDS were reviewed. Patient characteristics, clinical presentation, histologic findings, and treatment and survival data were extracted from each case report and review. DATA SYNTHESIS: Data were available on 792 patients (from 40 reported series) with non-AIDS-associated primary central nervous system lymphoma and 315 patients (from 32 series) with AIDS-associated primary central nervous system lymphoma. Patients with AIDS initially consulted a physician more often when they had global neurologic symptoms compared with patients without AIDS, with more than 50% of the lesions on computed tomographic (CT) scans in patients with AIDS being ring-enhancing and multifocal, a pattern rarely described in immunocompetent patients. The overall survival of the patients without AIDS was 18.9 months compared with 2.6 months for patients with AIDS, with substantial differences remaining even for subgroups of patients similarly treated with radiation and chemotherapy.
CONCLUSION: Primary central nervous system lymphoma is probably a substantially different disease in persons with and without AIDS with regard to patient characteristics, clinical and radiographic presentation, and prognosis. Recent advances in the treatment of this disease in patients without AIDS have not largely affected patients with AIDS. Substantial improvements in survival in these patients await advances in controlling their human immunodeficiency virus-associated disease.

Entities:  

Mesh:

Year:  1993        PMID: 8239229     DOI: 10.7326/0003-4819-119-11-199312010-00007

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  85 in total

Review 1.  Ongoing protocols for non-AIDS primary central nervous system lymphoma.

Authors:  K Hoang-Xuan; J Y Delattre
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

2.  A 59 year old man with progressive spinal cord and peripheral nerve dysfunction culminating in encephalopathy: Edinburgh advanced clinical neurology course, 1999.

Authors:  R Al-Shahi; C P Warlow; G H Jansen; C J Frijns; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

3.  Primary central nervous system lymphoma and subcutaneous metastases.

Authors:  B Al Bahrani; C Henderson; G Delaney
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

4.  Immunotherapy of a murine T cell lymphoma localized to the brain.

Authors:  V K Ghant; N S Hiramoto; G Y Gillespie; D K Gauthier; R N Hiramoto
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

5.  Multiple calcified primary central nervous system lymphoma with immunodeficiency in a child.

Authors:  Jing-Qi Zhu; Nan-Xin Hao; Wei-Qun Bao; Xiang-Ru Wu
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

6.  Primary pituitary lymphoma in an immunocompetent patient: a rare clinical entity.

Authors:  Yaxiong Li; Yuekang Zhang; Jianguo Xu; Ni Chen
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

7.  Hemorrhage and VEGF expression in a case of primary CNS lymphoma.

Authors:  James Rubenstein; Nancy Fischbein; Ken Aldape; Eric Burton; Marc Shuman
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

8.  Long-term survival in AIDS-related primary central nervous system lymphoma.

Authors:  Neel K Gupta; Amber Nolan; Antonio Omuro; Erin G Reid; Chia-Ching Wang; Gabriel Mannis; Michael Jaglal; Julio C Chavez; Paul G Rubinstein; Ann Griffin; Donald I Abrams; Jimmy Hwang; Lawrence D Kaplan; Judith A Luce; Paul Volberding; Patrick A Treseler; James L Rubenstein
Journal:  Neuro Oncol       Date:  2016-08-30       Impact factor: 12.300

9.  Neoplastic masquerade syndromes in patients with uveitis.

Authors:  Landon K Grange; Amr Kouchouk; Monica D Dalal; Susan Vitale; Robert B Nussenblatt; Chi-Chao Chan; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2013-11-06       Impact factor: 5.258

10.  Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas.

Authors:  Antonello Calderoni; Stefan Aebi
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.